TCA
OTLK icon

Transcend Capital Advisors’s Outlook Therapeutics OTLK Stock Holding History

Transcend Capital Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$17.4K – 506
2023
Q2 		$17.4K Hold
500
– – ﹤0.01% 483
2023
Q1 		$10.9K Hold
500
– – ﹤0.01% 478
2022
Q4 		$10.8K Hold
500
– – ﹤0.01% 489
2022
Q3 		$12K Hold
500
– – ﹤0.01% 480
2022
Q2 		$10K Hold
500
– – ﹤0.01% 497
2022
Q1 		$18K Hold
500
– – ﹤0.01% 514
2021
Q4 		$14K Buy
+500
New +$17.8K ﹤0.01% 487

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Transcend Capital Advisors's OTLK Position: Q3 2023 in Review

Transcend Capital Advisors sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 500 shares — an estimated $17.4K sold.

Transcend Capital Advisors first reported a position in OTLK in Q4 2021 and held it in 7 quarters. The position peaked at $18K in Q1 2022. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • Transcend Capital Advisors reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Transcend Capital Advisors sold 500 Outlook Therapeutics shares in Q3 2023, an estimated $17.4K.
  • Transcend Capital Advisors first reported a position in Outlook Therapeutics in Q4 2021 and held it in 7 quarters.
  • Transcend Capital Advisors's Outlook Therapeutics position peaked at $18K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on Transcend Capital Advisors's 13F filing for Q3 2023, filed 31 Oct 2023.